Celgene buys Gloucester Pharmaceuticals for $640 million to bolster its anticancer drug pipeline

Client(s) Celgene Corporation

Jones Day advised Celgene Corporation in its acquisition of Gloucester Pharmaceuticals. The acquisition will aid in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Under the terms of the merger agreement, Celgene will acquire Gloucester Pharmaceuticals for $340 million in cash plus $300 million in future U.S. and international regulatory milestone payments.